Biotest AG

Common Name
Biotest
Country
Germany
Sector
Healthcare
Industry
Biotechnology
Employees
2,495
Ticker
BIO
Exchange
HANSEATISCHE WERTPAPIERBOERSE HAMBURG
Description
Biotest AG is a biotechnology and pharmaceutical company that specializes in the research, development, and manufacturing of plasma protein products and biotherapeutic drugs. Its primary function is t...

Biotest's GHG Emissions Data Preview

In 2023, Biotest completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources) and Scope 2 (indirect emissions from purchased energy).

However, Biotest has not published a category-level breakdown of its Scope 3 emissions, limiting visibility into specific value chain sources.

Metric (tCO2e)2023202220212020 - 2017
Total Scope 1
Copy restricted. Please purchase to unlock this data.
a
Copy restricted. Please purchase to unlock this data.
Copy restricted. Please purchase to unlock this data.
0000000
Total Scope 2
Unspecified Calculation Method
Copy restricted. Please purchase to unlock this data.
a
Copy restricted. Please purchase to unlock this data.
Copy restricted. Please purchase to unlock this data.
0000000
Total Scope 3
Copy restricted. Please purchase to unlock this data.
Copy restricted. Please purchase to unlock this data.
Copy restricted. Please purchase to unlock this data.
0000000
Total Scope 1 Revenue Intensity (tCO2e/$M)
Copy restricted. Please purchase to unlock this data.
Copy restricted. Please purchase to unlock this data.
Copy restricted. Please purchase to unlock this data.
0000000
Download Data

Verified Sources Behind Biotest’s Greenhouse Gas (GHG) Emissions Data

Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Biotest’s data sources below and access millions more through our Disclosure Search.

a. Biotest's Non-financial report 2023
a. Biotest's Non-financial report 2023
b. Biotest's Sustainability Report 2020
b. Biotest's Sustainability Report 2020

Insights into Biotest's Operational Emissions

In 2023, the total operational greenhouse gas (GHG) emissions of Biotest amounted to 33,765 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2). a

Compared to 2020, the total operational greenhouse gas (GHG) emissions of Biotest increased by 24.42%, suggesting that the company faced challenges in reducing its emissions from its core operations. a b

Biotest's Scope 1 Emissions Over Time

2020202305 k10 k15 k20 ktCO2e-1%
  • Total Scope 1
  • Year-over-Year Change

What are Biotest's Scope 1 emissions?

In 2023, the total Scope 1 emissions of Biotest were 18,301 metric tons of CO₂ equivalent (tCO₂e). a

Compared to the previous year (2020), Biotest's Scope 1 emissions decreased by 1.47%, highlighting the company's efforts to lower direct emissions from assets it owns or controls. a b

What are Biotest's Scope 2 emissions?

In 2023, Biotest reported Scope 2 greenhouse gas (GHG) emissions of 15,464 tCO₂e without specifying the calculation method. a

Has Biotest reduced its Scope 2 emissions over time?

Compared to the previous year (2020), Biotest's Scope 2 emissions (Unspecified Calculation Method) rose by 80.58% in 2023, suggesting that the company faced challenges in reducing emissions from purchased electricity and energy a b

What methodology does Biotest use for Scope 2 reporting?

In 2023, Biotest reported its Scope 2 emissions using an unspecified methodology. a

Biotest's Scope 2 Emissions Over Time

2020202304 k8 k12 k16 ktCO2e
  • Total Scope 2 (Unspecified Calculation Method)

Insights into Biotest’s GHG Emissions Intensity Compared to Industry Peers

In 2020, Biotest reported Scope 1 greenhouse gas (GHG) emissions of 18,574.4 tCO₂e and total revenues of USD 384 millions. This translates into an emissions intensity of 48.41 tCO₂e per millions USD. b

Biotest's Scope 1 Emissions Intensity Compared to Peers

101001,00020,000200,000Scope 1 Emissions (tCO2e)2202002,00020,000Revenues (Millions of USD)RemeGenYear: 2024Scope 1: 54 tCO2eRevenue: $M 234Scope 1 Intensity: 0.23 tCO2e/$MIdorsiaYear: 2024Scope 1: 733 tCO2eRevenue: $M 124Scope 1 Intensity: 5.90 tCO2e/$MInsmedYear: 2024Scope 1: 1,666 tCO2eRevenue: $M 364Scope 1 Intensity: 4.58 tCO2e/$MShanghai Junshi BiosciencesYear: 2024Scope 1: 5,308 tCO2eRevenue: $M 267Scope 1 Intensity: 19.88 tCO2e/$MFrontage HoldingsYear: 2023Scope 1: 2,883 tCO2eRevenue: $M 2,027Scope 1 Intensity: 1.42 tCO2e/$MAkesoYear: 2024Scope 1: 6,408 tCO2eRevenue: $M 318Scope 1 Intensity: 20.17 tCO2e/$MSK BiopharmaceuticalsYear: 2024Scope 1: 414 tCO2eRevenue: $M 373Scope 1 Intensity: 1.11 tCO2e/$MSK BioscienceYear: 2023Scope 1: 5,863 tCO2eRevenue: $M 289Scope 1 Intensity: 20.28 tCO2e/$MZai LabYear: 2023Scope 1: 15 tCO2eRevenue: $M 267Scope 1 Intensity: 0.06 tCO2e/$MOxford Nanopore TechnologiesYear: 2024Scope 1: 313 tCO2eRevenue: $M 230Scope 1 Intensity: 1.36 tCO2e/$MZhifeiYear: 2023Scope 1: 14,211 tCO2eRevenue: $M 7,446Scope 1 Intensity: 1.91 tCO2e/$MKintor PharmaceuticalYear: 2021Scope 1: 29 tCO2eRevenue: $M 5Scope 1 Intensity: 5.35 tCO2e/$MSamsung BiologicsYear: 2023Scope 1: 69,262 tCO2eRevenue: $M 2,891Scope 1 Intensity: 23.96 tCO2e/$MAscendis PharmaYear: 2024Scope 1: 62 tCO2eRevenue: $M 443Scope 1 Intensity: 0.14 tCO2e/$M3SBioYear: 2024Scope 1: 13,304 tCO2eRevenue: $M 1,364Scope 1 Intensity: 9.75 tCO2e/$MBiontechYear: 2024Scope 1: 2,405 tCO2eRevenue: $M 3,341Scope 1 Intensity: 0.72 tCO2e/$MPharmaron BeijingYear: 2024Scope 1: 34,268 tCO2eRevenue: $M 1,682Scope 1 Intensity: 20.37 tCO2e/$MValnevaYear: 2024Scope 1: 1,277 tCO2eRevenue: $M 176Scope 1 Intensity: 7.24 tCO2e/$MWuXi Biologics (Cayman)Year: 2023Scope 1: 32,687 tCO2eRevenue: $M 2,603Scope 1 Intensity: 12.56 tCO2e/$MAlphamab OncologyYear: 2023Scope 1: 3,970 tCO2eRevenue: $M 34Scope 1 Intensity: 117.90 tCO2e/$MBioMarin PharmaceuticalYear: 2022Scope 1: 14,000 tCO2eRevenue: $M 2,096Scope 1 Intensity: 6.68 tCO2e/$MGenor Biopharma HoldingsYear: 2022Scope 1: 18 tCO2eRevenue: $M 3Scope 1 Intensity: 7.17 tCO2e/$MIonis PharmaceuticalsYear: 2024Scope 1: 2,616 tCO2eRevenue: $M 705Scope 1 Intensity: 3.71 tCO2e/$MZealand PharmaYear: 2024Scope 1: 145 tCO2eRevenue: $M 9Scope 1 Intensity: 16.60 tCO2e/$MBiotestYear: 2020Scope 1: 18,574 tCO2eRevenue: $M 384Scope 1 Intensity: 48.41 tCO2e/$M

How does Biotest's GHG emissions intensity compare to its peers?

In 2020, Biotest reported a Scope 1 emissions intensity of 48.41 tCO₂e per millions USD. Compared to the peer group median of 6.29 , this places the company above its industry benchmark, indicating it is less carbon-efficient than most competitors. b

Where does Biotest rank on GHG emissions intensity within its industry?

In 2020, Biotest ranked 24 out of 24 companies in its industry peer group, based on Scope 1 emissions intensity (measured in tCO₂e per millions USD). b

This places Biotest among the least efficient performers, with one of the highest emissions intensities in its sector. b

Want Full Access to Biotest's GHG Emissions Dataset?
Sign Up